4月22日ETF晚报丨多只医药生物板块ETF上涨；金价大涨，黄金主题ETF规模创新高

ETF Industry News - The three major indices mostly declined, with several ETFs in the pharmaceutical and biotechnology sector rising, such as the Huatai-PB Innovation Drug ETF (517120.SH) up 3.23% and the Hong Kong-Shenzhen Innovation Drug ETF (159622.SZ) up 2.73% [1] - The pharmaceutical sector continues to rebound, particularly in the innovative drug sub-sector, driven by recent tariff increases between China and the US, which may benefit domestic innovation [2] - Gold prices surged, leading to record inflows into gold-themed ETFs, with 14 gold-themed ETFs collectively attracting over 51 billion yuan from January 1 to April 18, 2025, and their total asset size reaching 145.1 billion yuan, more than doubling from the end of 2024 [3] - Major funds increased their holdings in four leading CSI 300 ETFs during the first quarter, with a total investment of approximately 4.471 billion yuan [4] Market Overview - On April 22, the Shanghai Composite Index rose by 0.25% to 3299.76 points, while the Shenzhen Component Index fell by 0.36% and the ChiNext Index dropped by 0.82% [5] - In terms of sector performance, retail, construction materials, and transportation sectors led the gains, while media, communication, and computer sectors lagged behind [7] ETF Performance - The average performance of commodity ETFs was the best among various categories, with an average increase of 2.78%, while stock-themed index ETFs had the worst performance with an average decline of 0.25% [10] - The top-performing ETFs included the Huatai-PB Innovation Drug ETF (517120.SH) and the Hong Kong-Shenzhen Innovation Drug ETF (159622.SZ), with daily returns of 3.23% and 2.73%, respectively [12][13] Trading Activity - The top three ETFs by trading volume included the CSI 300 ETF (510300.SH) with a trading volume of 2.919 billion yuan, followed by the South China A500 ETF (159352.SZ) at 2.652 billion yuan and the A500 ETF (159338.SZ) at 2.339 billion yuan [15][16]